argenx (ARGX) vs Roivant Sciences (ROIV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Roivant Sciences (ROIV) has outperformed argenx (ARGX) over the past year, gaining 115.6% versus a gain of 16.4%. Over five years, ROIV leads with a +477.2% price change compared with +216.1% for ARGX. argenx is the larger company by market cap ($51.88 billion vs $24.75 billion), about 2.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARGX | ROIV |
|---|---|---|
| Share price | $825.00 | $34.26 |
| Market cap | $51.88B | $24.75B |
| 1-day change | -11.14% | -1.41% |
| YTD return | +10.40% | +60.14% |
| 1-year return | +16.44% | +115.57% |
| 5-year return | +216.08% | +477.24% |
| P/E ratio (TTM) | 31.44 | — |
| Forward P/E | 23.76 | — |
| EPS (TTM) | $26.24 | $-0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $8.26M |
| Revenue growth (YoY) | — | -71.57% |
| Net income (latest FY) | $1.29B | $-299.77M |
| Operating margin | — | -6235.69% |
| Net margin | — | -3629.19% |
| 52-week high | $1,072.75 | $42.50 |
| 52-week low | $661.85 | $15.90 |
| Distance from 52-week high | -23.09% | -19.39% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +43.06% | +40.34% |
| Average volume | 283.40K | 7.02M |
| Shares outstanding | 62.89M | 722.32M |
| Employees | 1,863 | 721 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- argenx is about 2.1 times larger than Roivant Sciences by market value ($51.88B vs $24.75B).
- ROIV has outperformed ARGX by 99.1 percentage points over the past year.
About argenx
ARGX stock →argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,863 employees
About Roivant Sciences
ROIV stock →Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 721 employees
ARGX vs ROIV FAQ
Which is bigger, argenx or Roivant Sciences?
argenx (ARGX) is larger, with a market capitalization of $51.88B compared with $24.75B for Roivant Sciences (ROIV).
Which stock has performed better over the past year, ARGX or ROIV?
ROIV returned +115.57% over the past 12 months, compared with +16.44% for ARGX (price return, excluding dividends). Past performance does not predict future results.
Are argenx and Roivant Sciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for argenx and Biotechnology: Pharmaceutical Preparations for Roivant Sciences.